NCT04770337 is a NA clinical trial of STARSTIM device in Refractory Epilepsy, sponsored by Neuroelectrics Corporation.

Who is sponsoring NCT04770337?

NCT04770337 is sponsored by Neuroelectrics Corporation.

What drugs are being tested in NCT04770337?

Interventions in NCT04770337: STARSTIM device, Sham Device.

What condition does NCT04770337 study?

NCT04770337 studies Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic.

Is NCT04770337 still recruiting?

NCT04770337 is currently completed. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT04770337

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

Completed NA Last updated 8 April 2026

What this trial tests

NA trial testing STARSTIM device in Refractory Epilepsy in 127 participants. Completed in 12 January 2026.

Timeline

25 October 2021

Primary endpoint
12 January 2026

12 January 2026

Quick facts

Lead sponsor	Neuroelectrics Corporation
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	127
Start date	25 October 2021
Primary completion	12 January 2026
Estimated completion	12 January 2026
Sites	32 locations across Belgium, France, United States, Spain

Drugs / interventions tested

STARSTIM device
Sham Device — full drug profile →

Conditions studied

Refractory Epilepsy — all drugs for Refractory Epilepsy →
Focal Seizure — all drugs for Focal Seizure →
Seizures, Focal — all drugs for Seizures, Focal →
Seizures — all drugs for Seizures →

Sponsor

Neuroelectrics Corporation — full company profile →

Who can join

9 and older, any sex, with Refractory Epilepsy or Focal Seizure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse events will be collected and evaluated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.
Czura CJ, Bikson M, Charvet L, Chen JDZ, et al · · 2022 · cited 13× · PMID 35911909 · DOI 10.3389/fneur.2022.897124

Verify or expand the search:

Other recruiting trials for Refractory Epilepsy

Currently open trials in the same condition.

NCT06425029 — Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application · NA · recruiting
NCT06524479 — Investigating the Functional Characteristics During Wakefulness and Sleep Based on SEEG · NA · recruiting
NCT06241963 — High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy · NA · recruiting
NCT06396494 — An Automated Navigation System for Deep Brain Electrode Implantation · active not recruiting
NCT05493722 — Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy · EARLY_PHASE1 · recruiting

Other Neuroelectrics Corporation trials

Trials by the same sponsor.

NCT02866240 — Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04770337 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neuroelectrics Corporation
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04770337.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing